welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
Abstracts & Posters

P4.1 Puberty is delayed or absent in Duchenne Muscular Dystrophy boys on chronic glucocorticoid therapy

key information

source: Neuromuscular Disorders

year: 2011

authors: M.M. Rutter, S.R. Rose, J. Collins, H. Sucherew, B.L. Wong, I. Rybalsky


Chronic glucocorticoids (GCs) are standard therapy and slow disease progression in Duchenne Muscular Dystrophy (DMD). However, GCs cause adverse endocrine effects, including pubertal delay, growth failure and osteoporosis. Absent/delayed puberty is an important problem in DMD which, in turn, negatively impacts bone health, growth, self esteem and muscle strength. The prevalence in DMD is unknown, and it is frequently under-recognized and untreated.

The objective is to determine the prevalence of absent /delayed puberty in DMD boys on GC therapy.

organization: Cincinnati Children’s Hospital Medical Center, USA

DOI: 10.1016/j.nmd.2011.06.966

read more